AXAM Therapeutics

AXAM Therapeutics explores the epigenetic paradigm to disrupt the drug discovery concepts in human chronic diseases. Our vision took the source from the pioneering work of the founder Khelifa Arab at the German Cancer Research Center (DKFZ) and Institute of Molecular Biology Mainz (IMB) on the epigenetic regulation of tumor and metastasis suppressor genes by regulatory RNAs and R-loops structures. AXAM developed novel tools to define tumor epigenome weakness that enable us to select target proteins suitable for innovative drug development, i.e, small molecules and/or biologics. AXAM spearheaded a research therapeutic program in oncology and gathered two experienced cancer epigenetics and business strategy members in a creative team, aiming to reinforce the team with digital chemistry and drug developer experts. AXAM Therapeutics aims to fight against lethal chronic diseases and reinvest profits into sustainable epigenetic research.